Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Return on Equity (2021 - 2025)

Cytek Biosciences (CTKB) has disclosed Return on Equity for 5 consecutive years, with 0.18% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity fell 17.0% year-over-year to 0.18%, compared with a TTM value of 0.18% through Dec 2025, down 17.0%, and an annual FY2025 reading of 0.18%, down 17.0% over the prior year.
  • Return on Equity was 0.18% for Q4 2025 at Cytek Biosciences, down from 0.03% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.01% in Q3 2021 and bottomed at 1.71% in Q1 2021.
  • Average Return on Equity over 5 years is 0.18%, with a median of 0.02% recorded in 2024.
  • The sharpest move saw Return on Equity surged 171bps in 2022, then dropped -17bps in 2025.
  • Year by year, Return on Equity stood at 0.01% in 2021, then decreased by -21bps to 0.01% in 2022, then crashed by -608bps to 0.03% in 2023, then soared by 49bps to 0.02% in 2024, then plummeted by -1099bps to 0.18% in 2025.
  • Business Quant data shows Return on Equity for CTKB at 0.18% in Q4 2025, 0.03% in Q3 2025, and 0.02% in Q2 2025.